Alterity Therapeutics (ATHE) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NanoViricides (NNVC) has outperformed Alterity Therapeutics (ATHE) over the past year, losing 10.2% versus a loss of 56.7%. Over five years, NNVC leads with a -76.5% price change compared with -85.4% for ATHE. NanoViricides is the larger company by market cap ($29.1 million vs $29.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | NNVC |
|---|---|---|
| Share price | $1.52 | $1.14 |
| Market cap | $29.02M | $29.13M |
| 1-day change | -8.16% | -2.56% |
| YTD return | -50.65% | +0.88% |
| 1-year return | -56.70% | -10.24% |
| 5-year return | -85.38% | -76.54% |
| EPS (TTM) | $-0.90 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-8.22M |
| 52-week high | $5.89 | $1.93 |
| 52-week low | $1.52 | $0.85 |
| Distance from 52-week high | -74.19% | -40.93% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +771.71% | +426.32% |
| Average volume | 89.63K | 356.86K |
| Shares outstanding | 19.09M | 25.55M |
| Employees | 11 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed ATHE by 46.5 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ATHE vs NNVC FAQ
Which is bigger, Alterity Therapeutics or NanoViricides?
NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $29.02M for Alterity Therapeutics (ATHE).
Which stock has performed better over the past year, ATHE or NNVC?
NNVC returned -10.24% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.